What's Happening?
Zenzi Pharmaceutical Industries Pvt. Ltd., a Maharashtra-based contract manufacturer, has been placed on Import Alert 66-79 by the U.S. Food and Drug Administration (FDA). This action was taken after the company failed to respond to three successive Section
704(a)(4) requests for records between October and November 2024. The FDA's Center for Drug Evaluation and Research (CDER) issued the import alert on February 12, 2025, one day before a warning letter was sent. The warning letter, signed by Francis Godwin, Director of the Office of Manufacturing Quality, explicitly stated that the FDA had "no indication of the level of quality assurance for drugs listed as manufactured at your facility." This indicates that the import alert was triggered by the absence of verifiable quality data rather than a documented Current Good Manufacturing Practice (CGMP) deficiency found during an inspection. The initial electronic request was sent on October 29, 2024, followed by a written request on November 7. A response from Zenzi's Vice President of Quality on November 13 denied manufacturing the product in question, a claim contradicted by records provided by the product owner. A third request on November 15 received no reply.
Why It's Important?
This FDA action against Zenzi Pharmaceutical highlights the critical importance of compliance with U.S. regulatory requirements for all contract manufacturers supplying the U.S. market. The placement on Import Alert 66-79 means that all drugs manufactured at Zenzi's facility are now subject to detention or refusal upon entry into the U.S. under Section 801(a)(3) of the FD&C Act if they appear adulterated or misbranded. Furthermore, any new drug applications or supplements that list Zenzi as a manufacturer will have their approval withheld until CGMP compliance is confirmed. This has significant implications for pharmaceutical companies that rely on Zenzi for manufacturing, as it could disrupt their supply chains and delay market access for their products. The case also serves as a stark reminder to quality assurance directors and regulatory affairs leads at contract manufacturing organizations that Section 704(a)(4) requests carry the same legal weight as an inspection notice, and non-compliance can lead to swift enforcement action, impacting both the manufacturer and its clients.
What's Next?
Zenzi Pharmaceutical has 15 working days from the receipt of the warning letter to respond in writing to CDER. As part of their response, the company has the option to request a scheduled FDA inspection. The path for Zenzi to regain access to the U.S. market will depend heavily on the adequacy of its written response and whether the FDA decides to schedule a physical inspection of its Thane facility. Until CGMP compliance is confirmed, the import alert will remain in effect, impacting Zenzi's ability to supply drugs to the U.S. market and potentially affecting its business relationships with U.S.-based pharmaceutical companies. Other contract manufacturers supplying the U.S. market are likely to review their own procedures for responding to FDA records requests to avoid similar enforcement actions.
Beyond the Headlines
The FDA's decision to place Zenzi Pharmaceutical on import alert due to a failure to provide records, rather than an inspection-based deficiency, underscores a broader shift in regulatory enforcement. This approach emphasizes the importance of transparency and proactive data submission from manufacturers, even in the absence of physical inspections. It highlights that the burden of proof for quality assurance increasingly rests on the manufacturer to provide verifiable data upon request. This could lead to a re-evaluation of internal record-keeping and communication protocols within contract manufacturing organizations globally, as they recognize that a lack of response or contradictory information can trigger severe regulatory consequences. The case also raises questions about the due diligence processes of pharmaceutical companies when selecting contract manufacturers, emphasizing the need for robust oversight of their partners' regulatory compliance capabilities.
